Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of Tenaya Therapeutics (NASDAQ:TNYA) from a sell rating to a strong sell rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings upgraded shares of Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tenaya Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Tenaya Therapeutics Stock Performance

TNYA stock opened at $0.69 on Friday. The company has a market capitalization of $154.23 million, a PE ratio of -1.30 and a beta of 2.83. Tenaya Therapeutics has a one year low of $0.53 and a one year high of $2.35. The company’s 50 day moving average price is $0.76 and its two-hundred day moving average price is $0.75.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The firm had revenue of $1.11 million for the quarter, compared to the consensus estimate of $10.00 million. On average, research analysts predict that Tenaya Therapeutics will post -0.42 EPS for the current year.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Scientech Research LLC bought a new position in shares of Tenaya Therapeutics in the third quarter worth approximately $27,000. Geode Capital Management LLC raised its holdings in Tenaya Therapeutics by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company’s stock valued at $849,000 after buying an additional 17,820 shares during the last quarter. Mirador Capital Partners LP raised its holdings in Tenaya Therapeutics by 2.0% during the 2nd quarter. Mirador Capital Partners LP now owns 905,097 shares of the company’s stock valued at $669,000 after buying an additional 18,180 shares during the last quarter. Integrity Wealth Solutions LLC purchased a new stake in Tenaya Therapeutics during the 1st quarter valued at $27,000. Finally, Callan Family Office LLC purchased a new stake in Tenaya Therapeutics during the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.